Stocktoria
KYNTRA BIO, INC. KYNB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-11-14
KYNTRA BIO, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -712.7% | -507.8% | -689.5% | -213.9% | -122.6% |
| Net margin | 2848.6% | -160.6% | -607.3% | -208.7% | -123.3% |
| FCF margin | -74.7% | -466.8% | -678.5% | -106.4% | -37.2% |
| Return on assets | 153.4% | -22.2% | -67.1% | -48.1% | -37.5% |
| Return on equity | -610.7% | 21.1% | 139.2% | 1369.2% | -126.6% |
| Current ratio | 3.39 | 1.47 | 1.52 | 1.80 | 2.10 |
| Revenue growth | -78.3% | -36.7% | -66.7% | -40.2% | 33.5% |
Source: SEC EDGAR filings · CIK 0000921299 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.